NewAmsterdam Pharma Company N.V. cash flow to debt ratio of -73.16K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

NewAmsterdam Pharma Company N.V.'s free cash flow has increased -7.04% from $-159.24M last year to $-148.03M, signaling increasing performance

NewAmsterdam Pharma Company N.V.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

NewAmsterdam Pharma Company N.V.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

NewAmsterdam Pharma Company N.V. has a net cash position, so leverage is healthy.

NewAmsterdam Pharma Company N.V. earns at least as much interest as it pays. Interest obligations are fully covered.

NewAmsterdam Pharma Company N.V.'s profit margin has decreased (587.26%) in the last year from -530.25% to -3.64K%, signaling decreasing performance

NewAmsterdam Pharma Company N.V.'s short-term assets of $675.70M exceed its short-term liabilities of $85.79M

NewAmsterdam Pharma Company N.V.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

NewAmsterdam Pharma Company N.V.'s return on equity of -38.33%, is lower than 15.00%, indicating bad performance

NewAmsterdam Pharma Company N.V.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

NewAmsterdam Pharma Company N.V. had positive net income in only 0 out of 5 years, indicating unstable earnings

NewAmsterdam Pharma Company N.V. has negative free cash flow, indicating the company is burning cash rather than generating it

NewAmsterdam Pharma Company N.V. has negative free cash flow, indicating cash burn

NewAmsterdam Pharma Company N.V.'s yearly earnings has increased -15.64% since last year from $-241.60M to $-203.82M, signaling increasing performance

NewAmsterdam Pharma Company N.V.'s yearly revenue has decreased 50.61% since last year from $45.56M to $22.50M, signaling decreasing performance

ROIC -38.70% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

NewAmsterdam Pharma Company N.V.'s 3-year revenue CAGR of -39.71% is negative, indicating declining revenue over the past 3 years

NewAmsterdam Pharma Company N.V. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

NewAmsterdam Pharma Company N.V. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

NewAmsterdam Pharma Company N.V. is overvalued relative to its fair value price of 2.52 based on Discounted Cash Flow model

NewAmsterdam Pharma Company N.V. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

NewAmsterdam Pharma Company N.V. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

NewAmsterdam Pharma Company N.V. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

NewAmsterdam Pharma Company N.V. has insufficient data to evaluate this check.

NewAmsterdam Pharma Company N.V. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

NewAmsterdam Pharma Company N.V. has a price-to-book ratio of 5.47x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

NewAmsterdam Pharma Company N.V. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue